community download

Presentation: Matrix-M™ adjuvant

Matrix-MTM (saponin based adjuvant) is not equivalent to or synonymous with:
– ISCOMs (or ”classical” ISCOMs)

With 40 nm particles stabilized with cholesterol and phosphplipid, reduced reactogenicity vs previous saponin adjuvants, balanced Th1/Th2 stimulation of antibody and cellular response, and confirmed efficacy and safety in animals and humans; this really is an exciting piece of R&D. GMP material also available.

Matrix-M™ Influenza Study Conclusions Phase I Pandemic and Seasonal Elderly demonstrated:
• Safe, excellent tolerability
• Strong HI and VNA immune responses
• Exceeds EMA criteria and non-adjuvanted comparator vaccines
• Induces cross-reactive humoral responses
• Elicits pronounced cellular responses
• Dose-sparing capacity
• Potential to improve clinical efficacy in target populations

Why not download the full presentation and discover more about Matrix-M™ adjuvant elicits strong humoral and cellular immune responses in clinical influenza trials:
Phase I seasonal influenza trial in the elderly
Phase I pandemic influenza trial
Combined study data shows excellent safety profile
Dr Anders Kärnell, Chief Medical Officer, Isconova


Some quick details

Email Address:*
First name:*
Last name:*
Job Title:*

Remember my details Information

Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Privacy statement »
Manage your email preferences »

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.